COENZYME Q10

Course overview

COQ10 IS NOT FDA-APPROVED TO TREAT ANY MEDICAL CONDITION, ALTHOUGH IT IS WIDELY AVAILABLE OVER-THE-COUNTER AS A DIETARY SUPPLEMENT AND RECOMMENDED BY PRIMARY CARE PROVIDERS AND SPECIALISTS ALIKE. DISEASES SUCH AS NEURODEGENERATIVE DISEASES, FIBROMYALGIA, DIABETES, CANCER, MITOCHONDRIAL DISEASES, MUSCULAR DISEASES, AND HEART FAILURE ARE ASSOCIATED WITH DECREASED CIRCULATING LEVELS OF COQ10. STATIN DRUGS, OF NOTE, BLOCK THE PRODUCTION OF AN INTERMEDIATE IN THE MEVALONATE PATHWAY, A BIOCHEMICAL PATHWAY THAT LEADS TO THE PRODUCTION OF COQ10. THEREFORE, RESEARCHERS HYPOTHESIZE THAT STATIN DRUGS MAY DEPLETE THE BODY OF COQ10. AS MUSCLE PAIN AND CRAMPING ARE SUCH A COMMON ADVERSE EFFECT OF STATINS, THEY BELIEVE THIS DEPLETION IS THE CULPRIT. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, LATEST RESEARCH, AND RELEVANT INTERACTIONS PERTINENT TO COQ10 FOR MEMBERS OF THE INTERPROFESSIONAL TEAM TO TREAT PATIENTS WITH POTENTIALLY RELEVANT CONDITIONS.